6 best EDC platforms for hematology and blood disorder trials in 2026

A hematology trial rarely enrolls to plan on the first protocol version. Eligibility criteria shift as coagulation panels and cytogenetic markers refine the target population, and every amendment has to move through your database before the next site can screen a patient. Viedoc's electronic data capture software handles mid-study changes without downtime, backed by 24/7 support and a track record across more than 8,000 completed studies in 75-plus countries. This comparison reviews six EDC platforms against the criteria that matter most for hematology and blood disorder trials: amendment speed, complex lab data handling, multi-country recruitment support, and compliance readiness.

If you're leading data management or clinical operations for a growth-stage biotech or specialty pharma sponsor, you're working with a patient population measured in dozens, not thousands, so every dropped subject and every delayed amendment carries outsized weight. You need a database that can absorb a revised inclusion criterion or a new coagulation assay within days, not a change-control queue that stretches for weeks. Your data management team is lean, so the platform has to be one your own staff can configure, not one that routes every tweak through a vendor programmer.

Enterprise platforms built for large, multi-thousand-patient Phase III trials carry configuration overhead that a hematology program with a handful of sites rarely needs, and their programmer-dependent change control can turn a one-day amendment into a multi-week wait. Budget tools built for academic or single-site studies, meanwhile, lack the validation depth and audit trail rigor that a regulated sponsor submission demands. The platforms below were evaluated on how well they balance that trade-off for sponsors running complex, amendment-heavy studies in a rare or specialized therapeutic area.

Best EDC solutions: quick comparison

These six eClinical platforms represent the most evaluated options for growth-stage biotech and specialty pharma sponsors running hematology and blood disorder trials, reviewed across amendment speed, lab data handling, and compliance readiness.

1. Viedoc

Hematology protocols change as coagulation, cytogenetic, and flow cytometry data come in, and your database has to keep pace. Viedoc's EDC software is built for exactly that kind of mid-study change, with updates deployed without downtime across a base of more than 8,000 completed studies in 75-plus countries. The same no-code Viedoc Designer that builds the initial eCRF also handles the amendment, so a revised eligibility threshold doesn't have to wait on a vendor queue.

For a lean sponsor data management team running a single hematology program rather than a portfolio of large trials, that self-sufficiency matters as much as the technology itself. Unlimited user seats and study-based licensing mean the cost of adding a second site or a new biomarker assay doesn't scale with headcount, which keeps budget predictable as your trial moves from Phase I into Phase II. Real-time dashboards give your team visibility into enrollment and query status across every site, without waiting on a monthly report from a CRO.

Viedoc is ISO 27001 and SOC 2 certified, hosted on Microsoft Azure, and compliant with FDA 21 CFR Part 11, ICH GCP, EU Annex 11, and GDPR, along with HIPAA attestation for US protected health information. The platform has a 100% pass rate on FDA inspections associated with studies run on it to date. Support runs 24/7 across global offices, so a query raised by a site in one time zone doesn't sit unanswered until the next business day in another.

One data manager summed up the day-to-day experience simply. "Data capturing has been made easy because of Viedoc, it is incredibly robust and easy to navigate," said Khadija B., an Enterprise-tier user on G2.

• Study scale: 8,000+ global studies, with a 100% pass rate on associated FDA inspections
• Global reach: Used in 75+ countries and available in 40+ languages
• Uptime: 99.99% platform uptime, hosted on Microsoft Azure
• Compliance: 21 CFR Part 11, ICH GCP, EU Annex 11, GDPR, and HIPAA attestation; ISO 27001 and SOC 2 certified
• Pricing: Unlimited user seats, no per-user fees, transparent study-based licensing
• G2 rating: 4.5 out of 5, based on 237 reviews
  
  

  Launch, manage, and monitor clinical trials faster with intuitive EDC clinical trial software that keeps you compliant and audit ready.

2. Medidata

Medidata offers Rave EDC, an electronic data capture system at the center of the Medidata Clinical Cloud, a unified platform spanning study, patient, and data experiences. Rave EDC supports protocol amendments and mid-study changes without downtime, and it integrates with Medidata's eCOA, RTSM, and imaging applications for programs that need those modules connected. Medidata also offers Rave Lite, a simplified, pre-configured version aimed at Phase I, Phase IV, and post-market studies that need to move fast without a full-scale build. The 2025 ISR Benchmarking Report, based on independent sponsor evaluations, named Rave the most preferred EDC system. Rave EDC is used across all trial phases by large biopharmaceutical companies, global CROs, and MedTech organizations.

3. Veeva

Veeva offers Veeva EDC, part of the Vault Platform's clinical data suite, designed to support complex, multi-arm adaptive trial designs without downtime for mid-study changes. The platform uses role-based interfaces to speed source data verification and medical review, and it connects to Veeva's CTMS, eTMF, and RTSM applications through Veeva Connections for teams standardized on the Vault ecosystem. Veeva reports up to 50% faster study builds and up to nine times faster implementation of study changes compared with customers' prior systems. Eight of the top 20 biopharmaceutical companies have adopted Veeva EDC, and the platform is positioned for sponsors and CROs running studies of significant complexity across all trial phases.

4. Castor EDC

Castor EDC is a no-code, API-first electronic data capture platform built on a cloud-native architecture, with electronic consent and patient-reported outcomes tools on the same platform. Castor ranks among the top 5% of EDC providers for shortest build time, deploying more than 90% of studies within four weeks of contract signature, and low-complexity studies in as little as three to four weeks. The platform's open API connects to electronic health records, laboratory systems, and wearable devices, and Castor Catalyst uses AI-assisted extraction with human review to pull data from source documents into the EDC. Castor supports pharmaceutical, biotech, CRO, academic, and medical device customers running studies across 171 countries.

5. Medrio

Medrio offers Medrio CDMS/EDC, a cloud-based electronic data capture and clinical data management system built for small and scaling clinical teams. The platform uses a no-code, point-and-click study builder that lets teams go live within hours to days rather than weeks to months, and it supports both online and offline data capture at sites with limited connectivity. Medrio CDMS/EDC includes validated electronic records and signatures, full audit trails, and role-based access controls aligned with FDA 21 CFR Part 11, ICH E6(R2), HIPAA, and GDPR. The platform integrates with Medrio's own eConsent, eCOA, and RTSM modules, and serves MedTech, biotech, pharmaceutical, CRO, and animal health organizations from early feasibility through post-marketing trials.

6. Oracle

Oracle offers Oracle Life Sciences Clinical One Data Collection, a cloud platform that unifies electronic data capture with randomization and trial supply management on Oracle Cloud Infrastructure. The platform is built to collect datasets from multiple sources and harmonize them in a single environment, with AI-enabled tools intended to reduce manual configuration effort and support mid-study changes without a full re-validation cycle. Oracle Life Sciences has been positioned as a leader in the Everest Group PEAK Matrix for electronic data capture. The platform serves biopharmaceutical companies, CROs, and pharmaceutical manufacturers, and connects to Oracle's Safety One Argus for programs that need integrated adverse event reporting.

What to look for in EDC solutions for hematology and blood disorder trials

Amendment speed for biomarker-driven protocol changes

Hematology protocols evolve as coagulation panels, cytogenetic results, and flow cytometry data refine eligibility criteria and dosing, often mid-study rather than at a planned interim analysis. For your team, the question isn't whether an amendment will happen, but how many database days it costs each time it does.

Best-in-class platforms deploy a revised eCRF or edit check without a full re-validation cycle, moving from requirement to live database in days rather than weeks, and without pulling the study offline while sites wait. A platform that treats every amendment as a mini re-implementation adds weeks to a trial timeline your board is already watching closely.

Complex lab and biomarker data handling

A hematology eCRF has to accommodate coagulation assays, cytogenetic panels, bone marrow biopsy results, and central lab values that don't map cleanly onto a standard vital-signs template. The strongest platforms support custom edit checks and automated calculations, so a derived score doesn't have to be computed by hand at the site, and they connect directly to central lab and biomarker vendors through an open API rather than manual file transfer.

The strongest platforms also pair that lab depth with an integrated ePRO software module, so patients can report bleeding events, fatigue, or other subjective symptoms directly rather than leaving the record purely lab-driven. Manual transcription of lab values remains one of the most common sources of query volume in specialized trials, and it's largely avoidable with the right integration.

Multi-country recruitment support for a small patient population

Many hematologic conditions, especially inherited or rare blood disorders, have patient populations too small to recruit from a handful of sites, so your protocol likely spans multiple countries from the outset. Look for broad language support in both the clinician-facing database and any patient-reported outcomes tool, along with a track record of use across the regions where your target population actually lives.

Self-service configuration for a lean data management team

Growth-stage sponsors rarely staff a dedicated EDC programmer, so the person building and amending your database is often the same person reviewing your data. A genuinely no-code designer means your certified in-house team can make that change themselves, on the same day the protocol amendment is approved, rather than opening a ticket and waiting on a vendor's queue. Vendor dependency for every configuration change is a hidden cost that shows up as timeline risk, not a line item.

How to choose the right EDC solution for hematology and blood disorder trials

Step 1: Map your amendment cadence

Look back at how many protocol amendments your last comparable study required, and how long each one took from sponsor sign-off to a live database. That number, not a vendor's marketing claim, is the real benchmark for evaluating amendment speed.

Step 2: Assess your central lab and biomarker integration needs

Confirm which central labs, cytogenetic testing vendors, or companion diagnostic partners your protocol depends on, and check whether each candidate platform connects to them through a documented API rather than a manual export and import process.

Step 3: Size your recruitment footprint against language and country support

If your target population requires enrollment across more than a handful of countries, verify the platform's language coverage and country track record before you build, not after your first non-English site struggles with the interface.

Step 4: Evaluate how much your team can build without vendor support

Ask each vendor to walk your own data manager through building a sample amendment, not just watching a demo. The gap between what a sales team can do and what your team can do independently is where hidden costs live.

Step 5: Choose a platform that scales without a re-platform

A hematology program that succeeds in Phase I will move into Phase II with new sites, new countries, and a growing dataset, so the platform you pick now should support that growth without forcing a switch. Viedoc's EDC software is built to scale from a single-site Phase I study to a multi-country Phase II or III program on one platform, and you can book a demo to see how it handles a protocol like yours.

Frequently asked questions

What is the best EDC software for hematology and blood disorder trials?

Viedoc's EDC software is the strongest fit for growth-stage biotech and specialty pharma sponsors running hematology and blood disorder trials, thanks to its no-code Designer for handling frequent, biomarker-driven protocol amendments and its track record across more than 8,000 studies in 75-plus countries. The platform's unlimited user seats and study-based licensing keep costs predictable as a hematology program grows from a single-country Phase I study into a multi-country Phase II trial. Medidata is the category benchmark for large, complex Phase III programs at established pharmaceutical companies, though its enterprise configuration model carries more overhead than most growth-stage sponsors need. Castor EDC is a strong option for lower-complexity studies that value fast, self-service deployment over deep suite integration.

What should I look for when choosing an EDC platform for hematology trials?

Prioritize amendment speed, since hematology protocols change often as biomarker and lab data refine eligibility criteria. Confirm the platform connects to your central lab and biomarker vendors through a documented API rather than manual file transfer, and check that your own data management team can configure a change without vendor support. Compliance coverage matters too: confirm 21 CFR Part 11, ICH GCP, and GDPR support if you're recruiting across the US and EU, along with clear audit trail documentation for FDA and EMA review.

How long does it take to build and amend a study database on a modern EDC platform?

Timelines vary by platform and study complexity, but most modern EDC platforms report full study builds ranging from a few weeks to a few months. Viedoc's self-service customers can take a database live in as little as one day for simple studies, while professional-services-managed builds typically run 8 to 12 weeks from signed work order to go-live. Mid-study amendments on a no-code platform generally take days for minor updates and one to two weeks for more complex changes, compared with a longer change-control cycle on platforms that require vendor-side programming.

How does Viedoc's study build time compare to enterprise EDC platforms?

Viedoc offers a fast self-service path, with databases going live in as little as one day for simple studies, alongside a professional-services-managed path that typically runs 8 to 12 weeks from signed work order to go-live. Enterprise EDC platforms built for the largest Phase III programs generally carry a longer configuration cycle because of their broader scope and heavier validation requirements. For a hematology or blood disorder program running a handful of sites rather than a global mega-trial, that lighter overhead usually means a faster path to first patient in.

What compliance certifications should I look for in an EDC platform for a regulated hematology trial?

Look for FDA 21 CFR Part 11 compliance for electronic records and signatures, along with ICH GCP alignment for trial conduct standards. If you're recruiting across the European Union, confirm EU Annex 11 and GDPR support, and if any US protected health information is involved, confirm HIPAA attestation. Security certifications like ISO 27001 and SOC 2 indicate the vendor has independently verified controls around data handling, which matters when your IT and QA teams run their own vendor review.

Can a small sponsor data management team configure a hematology study without a vendor programmer?

Yes, on a genuinely no-code platform. Viedoc's Designer lets certified in-house data managers build the initial eCRF and every subsequent amendment without opening a ticket with a vendor programmer, which matters most for a lean sponsor team running one or two concurrent studies. Not every EDC platform offers this level of self-sufficiency, so it's worth testing during a demo rather than taking a vendor's word for it.

Making the right EDC choice for hematology and blood disorder trials

The six platforms compared here span a range, from enterprise suites built for large Phase III programs to no-code, self-service tools built for smaller, faster-moving trials. The global eClinical software market was estimated at more than $11 billion in 2025 and is projected to grow at roughly 14% annually. Across that market, mid-study amendment speed, not just initial build time, increasingly determines how well a platform serves a modern trial.

Match your choice to your organization's profile: a lean, single-country Phase I program benefits most from a fast, self-service platform, while a multi-country Phase II or III program with heavier compliance scrutiny may need deeper validation documentation and a broader integration footprint. Sponsors weighting speed and cost tend to favor no-code, self-service platforms, while those already invested in a larger eClinical suite often lean toward the bigger enterprise platforms. Geography matters too, since sponsors recruiting mainly across the EU tend to weight compliance credentials more heavily than a US-only program would.

Switching EDC platforms mid-trial carries real validation cost and timeline risk, so the choice made at study start compounds across the life of a hematology program more than it would in a larger, better-resourced trial.

Why Viedoc is the best EDC choice for hematology and blood disorder trials

Hematology and blood disorder trials rarely follow a static protocol, and Viedoc's EDC software is built around that reality. With more than 8,000 completed studies across 75-plus countries and 99.99% platform uptime, Viedoc handles mid-study amendments without taking your database offline while sites wait.

The same no-code Designer that builds your initial eCRF handles every amendment after it, so your own certified data managers stay in control of the timeline instead of waiting on a vendor queue. Unlimited user seats and transparent, study-based licensing mean your costs stay predictable as your program grows from Phase I into Phase II, and 24/7 support across global offices means a query never sits unanswered overnight.

Viedoc is ISO 27001 and SOC 2 certified, hosted on Microsoft Azure, and compliant with FDA 21 CFR Part 11, ICH GCP, EU Annex 11, GDPR, and HIPAA attestation, with a 100% pass rate on associated FDA inspections to date. Founded in Uppsala, Sweden in 2003, Viedoc has more than two decades of deployment behind it.

If you're weighing platforms for a hematology or blood disorder program, book a demo or request a proposal and we'll walk your team through amendment speed, lab data handling, and compliance credentials in the context of your own protocol.